• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by UroGen Pharma Ltd.

< Previous 1 2 3 4 Next >
UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023
May 04, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation
May 01, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis
April 30, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Present at H.C. Wainwright BioConnect Conference
April 25, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments
March 16, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023
March 09, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Present at Upcoming Investor Conferences
March 01, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer
February 15, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer
January 11, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
December 19, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 09, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
December 02, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer
December 01, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference
November 21, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma
November 14, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
November 10, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors
November 09, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
November 03, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers
October 11, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
FDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO® Admixture to 96 Hours Following Reconstitution
September 28, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors
September 12, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 09, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Upcoming 2022 Conferences
September 07, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
August 11, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
July 27, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Present at Upcoming Investor Conferences
May 18, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer
May 16, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting
May 13, 2022
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
< Previous 1 2 3 4 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap